#For clinicians

Written for prescribing clinicians, with full citation chains.

A 24-week Indian phase 3 trial found Sun Pharma's synthetic semaglutide non-inferior to Wegovy for percentage weight change.

A matched UK cohort linked tirzepatide use to lower weight, HbA1c and insulin needs in type 1 diabetes, but it was not randomized.

A 2026 practical guide organizes obesity prescribing decisions, but it is not a new trial and does not establish a semaglutide-tirzepatide winner.

A pooled STEP analysis found more gallbladder events with semaglutide 2.4 mg than placebo, but the absolute event rate remained low.

A 2026 systematic review links pediatric GLP-1 medicines with lower BMI or HbA1c, while highlighting gastrointestinal effects and long-term gaps.

A cross-sectional hospital study found more documented illness among neuropathy patients with GLP-1-based medication records, but no causal effect.

A 2026 review argues that GLP-1 rodent thyroid tumors reflect a human-irrelevant mechanism, but long-term human risk is not settled.

A U.S. model found semaglutide and tirzepatide cost-effective versus standard care for MASH, with major uncertainty around prices and assumptions.

A retrospective cohort linked oral semaglutide with fewer new cognitive-impairment cases than DPP-4 inhibitors, but it cannot prove prevention.

A papillary thyroid cancer case during semaglutide use cannot establish causation, and larger human studies have not confirmed excess risk.

A scoping review found more retinal vascular events reported with semaglutide than placebo, but the events were rare and estimates remain uncertain.

A lipid-based semaglutide formulation improved cell transport and glucose measures in diabetic rats, but it has not been tested in people.